Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia

Cancer

Volumn 101, Issue 12, 2004, Pages 2788-2801

  Kantarjian, Hagop ^a   Thomas, Deborah ^a   O'Brien, Susan ^a   Cortes, Jorge ^a   Giles, Francis ^a   Jeha, Sima ^a   Bueso Ramos, Carlos E ^a   Pierce, Sherry ^a   Shan, Jianqin ^a   Koller, Charles ^a   Beran, Miloslav ^a   Keating, Michael ^a   Freireich, Emil J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute lymphocytic leukemia (ALL); And dexamethasone (Hyper CVAD) regimen; Doxorubicin; Hyperfractionated cyclophosphamide; Long term follow up; Vincristine

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FLUCONAZOLE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; LACTATE DEHYDROGENASE; LEVOFLOXACIN; METHOTREXATE; METHYLPREDNISOLONE; RITUXIMAB; STEROID; VALACICLOVIR; VINCRISTINE;

ACUTE LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW SUPPRESSION; BONE PAIN; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM TUMOR; CHICKENPOX; CYTOMEGALOVIRUS INFECTION; DEPRESSION; DESQUAMATION; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG MEGADOSE; FOLLOW UP; HERPES; HIGH RISK PATIENT; HUMAN; ILEUS; INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MOOD DISORDER; MORTALITY; MUCOSA INFLAMMATION; MYCOSIS; NEPHROTOXICITY; NEUROTOXICITY; PHILADELPHIA 1 CHROMOSOME; PNEUMOCYSTOSIS; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PYREXIA IDIOPATHICA; RASH; SEPSIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CENTRAL NERVOUS SYSTEM NEOPLASMS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION; RISK; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 10044259800     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20668     Document Type: Article

References (48)

1. Faderl S, Jeha S, Kantarjian H. The biology and therapy of adult acute lymphoblastic leukemia. Cancer. 2003;98:1337-1354.
2. Gokbuget N, Hoelzer D, Arnold R, et al. Treatment of adult ALL according to protocols of the German Multicenter study group for adult ALL (GMALL). Hematol/Oncol Clin North Am. 2000;14:1307-1325.
3. Durrant IJ, Richards SM, Prentice HG, Goldstone AH. The Medical Research Council trials in adult acute lymphocytic leukemia. Hematol/Oncol Clin North Am. 2000;14:1327-1352.
4. Thiebaut A, Vernant JP, Degos L, et al. Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation: a follow-up report of the French protocol LALA 87. Hematol/Oncol Clin North Am. 2000;14:1353-1365.
5. Larson RA. Recent clinical trials in acute lymphocytic leukemia by the Cancer and Leukemia Group B. Hematol/Oncol Clin North Am. 2000;14:1367-1379.
6. Garcia-Manero G, Kantarjian H. The Hyper-CVAD regimen in adult acute lymphocytic leukemia. Hematol/Oncol Clin North Am. 2000;14:1381-1396.
7. Linker CA, Levitt LJ, O'Donnell M, et al. Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report. Blood. 1991;78:2814-2822.
8. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18:547-561.
9. Faderl S, Garcia-Manero G, Thomas DA, Kantarjian HM. Philadelphia chromosome-positive acute lymphoblastic leukemia-current concepts and future perspectives. Rev Clin Exp Hematol. 2002;6:142-160.
10. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004;103:4396-4407.
11. Kantarjian HM, Walters RS, Keating MJ, et al. Results of the vincristine, doxorubicin and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. J Clin Oncol. 1990;8:994-1004.
12. Wetzler M, Dodge RK, Mrozek K, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the Cancer and Leukemia Group B experience. Blood. 1999;93:3983-3993.
13. Goldstone AH, Prentice HG, Durant J, et al. Allogeneic transplant (related or unrelated donor) is the preferred treatment for adult Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). Results from the International ALL Trial (MRC UKALLXII/ECOG E2933) [abstract]. Blood. 2001;98:856a.
14. Goldstone A, Chopra R, Buck G, et al. The outcome of 267 Philadelphia positive adults in the International UKALL12/ECOG E 2993 study. Final analysis and the role of allogeneic transplant in those under 50 years [abstract]. Blood. 2003;102:80a
15. Barrett A, Horowitz M, Ash R, et al. Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 1992;79:3067-3070.
16. Hoelzer D. Which factors influence the different outcome of therapy in adults and children with ALL? Bone Marrow Transplant. 1989;4(Suppl. 1):98-100.
17. Zang M, Hoelzer D, Horowitz M, et al. Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. Ann Intern Med. 1995;123:428-431.
18. Sebban C, Lepage E, Vernant J, et al. Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. J Clin Oncol. 1994;12:2580-2587.
19. Rowe JM, Richards S, Burnett AK, et al. Favorable results of allogeneic bone marrow transplantation (BMT) for adults with Philadelphia (Ph)-chromosome-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR): results from the International ALL Trial (MRC UKALL XII/ECOG E2993) [abstract]. Blood. 2001;98:481a.
20. Nachman J, Sather H, Cherlow J, et al. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: A report from the Children's Cancer Group. J Clin Oncol. 1998;16:920-930.
21. Bürger B, Zimmermann M, Mann G, et al. Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol. 2003;21:184-188.
22. Pui C-H, Cheng C, Leung W, et al. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med. 2003;349:640-649.
23. Walter A, Hancock M, Pui C-H, et al. Secondary brain tumors in children treated for acute lymphoblastic leukemia at St. Jude children's Research Hospital. J Clin Oncol. 1998;16:3761-3767.
24. Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 2003;101:3809-3817.
25. Norwak-Göttl U, Ahlke E, Fleischhack G, et al. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration. Blood. 2003;101:2529-2533.
26. Schwartz C, Thompson EB, Gelber R, et al. Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia. J Clin Oncol. 2001;19:1040-1046.
27. Pui C-H, Evans WE. Acute lymphoblastic leukemia. N Engl J Med. 1998;339:605-615.
28. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90 - German-Austrian-Swiss ALL-BFM Study Group. Blood. 2000;95:3310-3322.
29. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana Farber Consortium Protocol 91-01. Blood. 2001;97:1211-1218.
30. Nachman JB, Harland NS, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998;338:1663-1671.
31. Stock W, Sather HN, Dodge RK. Outcome of adolescents and young adults with ALL: a comparison of Children's Cancer Group (CCG) and Cancer and Leukemia Group B (CALGB) regimens [abstract]. Blood. 2000;96:467a.
32. Boissel N, Auclerc MF, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003;21:774-780.
33. Schiffer CA. Differences in outcome in adolescents with acute lymphoblastic leukemia: a consequence of better regimens? Better doctors? Both? J Clin Oncol. 2003;21:760-761.
34. Peeters M, Koren G, Jakubovicz D, et al. Physician compliance and relapse rates of acute lymphoblastic leukemia in children. Clin Pharmacol Ther. 1988;43:228-232.
35. Eden OB, Stiller CA, Gerrard MP. Improved survival for childhood acute lymphoblastic leukemia: possible effect of protocol compliance. Pediatr Hematol Oncol. 1988;5:83-91.
36. Chessells J, Hall E, Prentice H, et al. The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: a report from the MRC Paediatric and Adult Working Parties. Leukemia. 1998;12:463-473.
37. Hoelzer D, Thiel E, Löffler H, et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood. 1988;71:123-131.
38. Taylor PRA, Reid MM, Brown N, Hamilton PJ, Proctor SJ. Acute lymphoblastic leukemia in patients aged 60 years and over: a population-based study of incidence and outcome. Blood. 1992;80:1813-1817.
39. Toyoda Y, Manabe A, Tsuchida M, et al. Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J Clin Oncol. 2000;18:1508-1516.
40. Lauer S, Shuster J, Mahoney D, et al. A comparison of early intensive methotrexate/metcaptopurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group phase III randomized trial. Leukemia. 2000;15:1038-1045.
41. Schmiegelow K, Björk O, Glomstein A, et al. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia. J Clin Oncol. 2003;21:1332-1339.
42. Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811. Blood. 1995;85:2025-2037.
43. Stock W, Yu D, Johnson J, et al. Intensified daunorubicin during induction and post-remission therapy of adult acute lymphoblastic leukemia (ALL): results of CALGB 19802 [abstract]. Blood. 2003;102:379a.
44. Thomas D, O'Brien S, Cortes J, et al. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood. 2004;104:1624-1630.
45. Romaguera JE, Khouri IF, Kantarjian H, et al. Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. Leuk Lymphoma. 2000;39:1-9.
46. Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high dose methotrexate/cytarabine followed by stem cell transplantation: an active regimen for aggressive mantle cell lymphoma. J Clin Oncol. 1998;16:3803-3809.
47. Dimopoulos MA, Weber D, Kantarjian H, et al. HyperCVAD for VAD-resistant multiple myeloma. Am J Hematol. 1996;52:77-81.
48. Tsimberidou AM, Kantarjian H, Cortes J, et al. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer. 2003;97:1711-1720.